06618 JD HEALTH
- 27.500
- +0.900+3.38%
JD HEALTH News
Intraday Overview | The Hang Seng Index entered a technical bull market, and the Tech Index rose more than 1.7%
Technology stocks strengthened; Shangtang and BYD Electronics rose more than 6%, and NIO rose more than 5%; Youbi Choice rose more than 15%, and the company took the lead in developing the “Tiangong” robot platform.
2023 年度報告
Tech giants face profit challenges: the market value of Huali Seven Shares evaporates by nearly 1 trillion US dollars
Large technology companies are facing a profit test. The seven major tech giants lost nearly 1 trillion US dollars in market capitalization last week, and market anxiety is rising.
JD.com's 1Q Revenue Likely Supported by Low-Price Strategy, Better User Experience -- Market Talk
JD.com's low-price strategy and user experience enhancement likely sustained its gross merchandise value growth momentum and supported 1Q revenue growth, Daiwa analysts John Choi and Robin Leung say in a research note.
Hong Kong Internet healthcare stocks fluctuated and recovered. Ping An Good Doctor fell nearly 4%, Jingdong Health fell nearly 3%, and Ali Health fell 1.4%.
Hong Kong Internet healthcare stocks fluctuated and recovered. Ping An Good Doctor fell nearly 4%, Jingdong Health fell nearly 3%, and Ali Health fell 1.4%.
Express News | Will JD Health start drug research and development? Response: We will not invest in the future if we are not in the business layout
Will JD Health start drug research and development? Response: It's not in the business layout, and we won't invest in the future
Gelonghui, April 7 | According to Pengpai, recently, JD Health launched a questionnaire on the consumption of pharmaceuticals and health products. Since the questionnaire topics covered topics such as new drug research and development, clinical trials, and patient recruitment, it sparked speculation that JD Health would begin drug development. On April 7, the relevant person in charge of JD Health responded that drug research and development is currently not in the business layout, and they will not participate in this field in the future.
JD Health (06618.HK): Three-party merchant ecosystem construction accelerates full coverage of online and offline medical scenarios
Recently, JD Health (06618.HK) announced its 2023 results. The company achieved revenue of 53.5 billion yuan in 2023, up 14.5% year on year over 46.7 billion yuan in the same period last year; by business, the company's own product revenue in 2023 was 45.65 billion yuan, up 13.1% year on year; service revenue was 7.88 billion yuan, up 23.7% year on year.
JD Health (6618.HK): Gross margin is expected to continue to recover, and service revenue is expected to maintain rapid growth
The company's profit in 2023 exceeded market expectations, and gross margin stopped falling and rebounded: According to the company's 2023 report, JD Health achieved operating income of 53.53 billion yuan in 2023 (+14.5% year-on-year); in 2023, the public
JD Health (06618.HK) 2023 Annual Report Performance Review: Reducing Costs and Increasing Efficiency to Develop New Quality Productivity Layout Medical Services
Incident: The company recently released its FY2023 performance report: During the reporting period, it achieved operating revenue of 53.53 billion yuan (+14.5%), of which 45.65 billion yuan (+13.1%) of self-operated operations and 7.88 billion yuan (+23.6 billion) of services
JD Health (6618.HK) 2023 Report Review: The number of merchants on the three sides increased dramatically, and the big model helped reduce costs and increase efficiency
Core view On March 20, 2023, JD Health announced its 2023 annual results. In 2023, the company achieved revenue of 53.53 billion yuan, an increase of 14.54% over the previous year, and achieved non-IFRS net profit
JD Health (6618.HK): Expanding the Tripartite Merchant Ecosystem to Help Return to an Endogenous Growth Path
Net profit was higher than expected; due to increased support from new merchants, profit growth in 2024 may weigh on JD Health 2H23's total revenue of 26.42 billion yuan, -0.3% year over year, lower than Visible Alpha (VA)
JD Health (6618.HK): Performance growth exceeds expectations, omnichannel business layout accelerates
Event: The company released its 2023 annual report, where review revenue grew steadily, and the number of third-party merchants rapidly expanded. In 2023, the company achieved revenue of 53.5 billion yuan (+14.5%), of which, 1. Pharmaceutical and health products sales business
Nomura Adjusts JD Health's Price Target to HK$44 to HK$37, Keeps at Buy
05:00 AM EDT, 03/22/2024 (MT Newswires) -- Nomura Adjusts JD Health's Price Target to HK$44 to HK$37, Keeps at Buy Price (HKD): $28.05, Change: $-4.05, Percent Change: -12.62%
A shares suddenly changed, and Hong Kong stocks followed the decline! WHAT HAPPENED?
Just now, A-shares have ushered in big changes! The Hong Kong stock market, the South Korean stock market, and the Australian stock market also fell.
Hong Kong Internet Healthcare Stocks Continue to Fall
Gelonghui March 22 | JD Health (6618.HK) fell 8.5%, Ali Health (0241.HK) fell 4.5%, and Zhongan Online (6060.HK) fell more than 4%.
JD Health's 2023 Profit Soars Almost Sixfold to Over 2 Billion Yuan
JD Health International (HKG:6618) recorded a nearly sixfold surge in attributable profit for the year ended Dec. 31, 2023, to 2.14 billion yuan from 380.1 million yuan in 2022, a Wednesday filing on
Express News | JD Health (06618.HK)'s revenue for the full year of 2023 was 53.53 billion yuan, compared to 46.736 billion yuan in the same period last year.
JD HEALTH-R: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
JD HEALTH: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Analysis
Price Target
No Data
